According to the current analysis of Reports and Data, the global Pulmonary arterial hypertension Market was valued at USD 6.02 billion in 2018 and is expected to reach USD 9.27 billion by the year 2026, at a CAGR of 5.6%. Pulmonary arterial hypertension is caused by the rise in pulmonary arterial pressure, which leads to an increase in the workload on the right side of the heart, which progresses the symptoms of PAH (Pulmonary arterial hypertension). The rise in the geriatric population, with the decrease in the levels of immunity, boosts up the market.
The global pulmonary arterial hypertension market is driving due to the prevalence of diseases like (Cirrhosis), Chronic lung diseases like emphysema, Asthma, etc. A person with PAH even can survive without treatment for a long time, but it is essential to treat it as the increased load on the right side of the heart can lead to heart failure. Treatment will help improve the quality of life. Habits such as smoking, tobacco, consumption of alcohol are expected to boost the prevalence of pulmonary arterial hypertension leading to increased demand for the treatment. World Health Organization (WHO) and the Centre for Disease Control and Prevention had suggested that there is a prevalence of PAH that reported 15 to 50 million cases per head. Rise in disease like asthma COPD and chronic lung disorder is expected to rise the PAH market growth. According to the Global Asthma Report 2018 about 1000 people worldwide die of asthma every day and it has affected more than 339 million people. The rise in health care awareness and an increase in medical expenditure is likely to boost the market.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2667
The report provides a panoramic view of the market and insights that will help formulate better business decisions. In addition to that, the study helps well-established companies and players gain a deeper understanding of the market and make informed decisions. The report also discusses in detail about the key factors influencing the market growth.
Key companies operating in the market include:
Actelion Pharmaceuticals Ltd(Switzerland), Novartis International AG (Switzerland), Gilead Sciences, Inc.(US), United Therapeutics Corporation(US), GlaxoSmithKline Plc. (GSK)(London), Pfizer Inc(US), Dong-A ST Co Ltd (South Korea), Bayer HealthCare(Germany), Merck Sharp & Dohme Corp (US) and Arena P.
The report covers an extensive analysis of the key market players in the market along with their business overview, expansion plans, and strategies. The report also focuses on recent strategic alliances in the market including mergers and acquisitions, joint ventures, partnerships, agreements, corporate and government deals, product launches, and brand promotions, among others.
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2667
The report aims to provide a better understanding of the market dynamics and the workings of the industry on a global level. To gain a deeper understanding of the industry, the global Pulmonary Arterial Hypertension market is further segmented on the basis of key geographical regions such as North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. The report also offers a country-wise analysis to provide crucial insights into market size, market growth, market revenue growth, and economic growth in each region.
On basis of product types and application offered by the Pulmonary Arterial Hypertension industry, the market is segmented into:
Product Outlook (Revenue in Million USD; 2016–2026)
- Prostacyclin and Prostacyclin Analogs
- Soluble Guanylate Cyclase Stimulators
- Endothelin Receptor Antagonists (ERAs)
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Calcium Channel Blockers
- Others
Technology Outlook (Revenue in Million USD; 2016–2026)
- Cuff-less BP monitoring devices
- Ambulatory monitors
- Novel technology smartphones and Bluetooth enabled telemonitoring
- Tele-monitoring
Application Outlook (Revenue in Million USD; 2016–2026)
- Early-stage Drug Candidates (Phase I & Phase II)
- Late-stage Drug Candidates (Phase III & Registration Phase
End-Use Outlook (Revenue in Million USD; 2016–2026)
- Hospital
- Clinic
The regional analysis covers:
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- Italy
- France
- BENELUX
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- A.E.
- South Africa
- Rest of MEA
To know more about the report @ https://www.reportsanddata.com/report-detail/pulmonary-arterial-hypertension-market
Benefits of Pulmonary Arterial Hypertension Market Report:
- Panoramic overview of the opportunities and risks in the Pulmonary Arterial Hypertension sector
- Study of recent innovations and developments in the industry
- Comprehensive study of the growth pattern of the Pulmonary Arterial Hypertension industry
- In-depth assessment of the competitive landscape of the key players of the Pulmonary Arterial Hypertension industry
- Analysis of the Pulmonary Arterial Hypertension market drivers, constraints, and opportunities
- Assessment of technological developments and latest trends of the industry
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2667
Thank you for reading our report. For customization or further inquiry, please get in touch with us. Our team will ensure the report is tailored according to your requirements.
Browse More Reports :
Hemoglobinopathies Market Growth
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Contact Us:
John W
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]
